期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氟喹诺酮类药物对伤寒沙门菌的防突变浓度测定 被引量：4

原文传递
导出
摘要 氟喹诺酮类药物因具有良好的抗菌活性而成为治疗伤寒的首选药，但由于药物的不合理应用，出现了伤寒沙门菌对氟喹诺酮类药物的敏感度下降、甚至耐药。伤寒沙门菌对喹诺酮类药物的耐药性主要是通过编码靶位基因突变，导致DNA旋转酶结构改变，使药物不能与酶-DNA复合物稳定结合，从而产生耐药。而防耐药突变浓度（mutant prevention concentration，MPC）概念的提出，
作者 李国涛 鲁猛厚
机构地区 中南大学湘雅医院感染病科
出处 《中华传染病杂志》 CAS CSCD 北大核心 2007年第5期276-278,共3页 Chinese Journal of Infectious Diseases
关键词 氟喹诺酮类药物 伤寒沙门菌 基因突变 浓度测定 prevention DNA旋转酶 防耐药突变浓度 DNA复合物
分类号 R516.3 [医药卫生—内科学]
  • 相关文献

参考文献15

  • 1Butt T, Ahmad RN, Salman M, et al. Changing trends in drug resistance among typhoid salmonellae in Rawalpindi, Pakistan. East Mediterr Health J, 2005, 11 : 1038-1044.
  • 2Howard AJ, Joseph TD, Bloodworth LL, et al. The emergence of ciprofloxacin resistance in Salmonella typhimurium. J Antimicrob Chemother, 1990, 26 : 296-298.
  • 3Lewin CS, Nandivada LS, Amyes SG. Muhiresistant Salmonella and fluoroquinolones. J Antimicrob Chemother, 1991, 27:147-149.
  • 4Zhao X, Drlica K. Restricting the selection of antibioticresistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis, 2001, 33 Suppl 3:S147-S156.
  • 5Zhao X, Eisner W, Perl-Rosenthal N, et al. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 2003, 47:1023-1027.
  • 6Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis, 2002, 185:561-565.
  • 7Drlica K. A strategy for fighting antibiotic resistance. ASM News, 2001, 67:27-33.
  • 8Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother, 1999, 43: 1756-1758.
  • 9Dong Y, Zhao X, Kreiswirth BN, et al. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2000, 44 : 2581-2584.
  • 10Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother, 1999, 43:2793-2797.

二级参考文献24

  • 1.药物制剂人体生物利用度和生物等效性试验指导原则中国药典 二部[M].,2000年版.附录.
  • 2..国家药品监督管理局令第13号药品临床试验管理规范[S].,1999..
  • 3[2]Zhao XL, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window[J]. J Infect Dis,2002,185(15 ):561-565.
  • 4[3]Lu T, Zhao X, Li XY,et al.Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin, and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus[J]. J Antimicrob Chemother,2003,52(1):61-64.
  • 5[4]Drlica K. The mutant selection concentration and antimicrobial resistance[J]. J Antimicrob Chemother, 2003,52(1):11-17.
  • 6[5]Drlica K. A strategy for fighting antibiotic resistance[J]. ASM News, 2001,67(1):27-33.
  • 7[6]Ho PL,Tse WS,Tsang K, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae:a case-control study[J]. Clin Infect Dis,2001,32:701-707.
  • 8[7]Zhao XL, Xu C, Domagala J, et al. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance[J]. Microbiology,1997,94(25):13991-13996.
  • 9Perry C M, Balfour J A B, Lamb H M. Gatifloxacin [J].Drugs, 1999,58(4) :683.
  • 10Nakashima M, Uematsu T, Kousuge K, et al. Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans [J]. Antimicrob Agents Chemother, 1995,39 : 2635.

共引文献67

同被引文献69

引证文献4

二级引证文献11

中华传染病杂志
2007年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部